Propranolol in Primary Progressive Aphasia
The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure. This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.
Study ID: 3476
NCT Number: NCT06066710
Principal Investigator: David Beversdorf, MD
Department: Neurology
Eligibility: Both men and women 50 years old to 100 years old. Does not accept healthy volunteers.
For questions about this study, please contact:
ClinicalTrialsInterest@health.missouri.edu(573) 882-7026
